EP0655924A4 - A COMBINATION OF MONOCLONAL ANTIBODIES AGAINST erbB-2 AND METHOD FOR THEIR USE. - Google Patents

A COMBINATION OF MONOCLONAL ANTIBODIES AGAINST erbB-2 AND METHOD FOR THEIR USE.

Info

Publication number
EP0655924A4
EP0655924A4 EP93906955A EP93906955A EP0655924A4 EP 0655924 A4 EP0655924 A4 EP 0655924A4 EP 93906955 A EP93906955 A EP 93906955A EP 93906955 A EP93906955 A EP 93906955A EP 0655924 A4 EP0655924 A4 EP 0655924A4
Authority
EP
European Patent Office
Prior art keywords
erbb
combination
monoclonal antibodies
monoclonal
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93906955A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0655924A1 (en
Inventor
Philip G Kasprzyk
Charles R King
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncologix Inc
Original Assignee
Oncologix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncologix Inc filed Critical Oncologix Inc
Publication of EP0655924A1 publication Critical patent/EP0655924A1/en
Publication of EP0655924A4 publication Critical patent/EP0655924A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP93906955A 1992-06-30 1992-10-21 A COMBINATION OF MONOCLONAL ANTIBODIES AGAINST erbB-2 AND METHOD FOR THEIR USE. Withdrawn EP0655924A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90655592A 1992-06-30 1992-06-30
US906555 1992-06-30
PCT/US1992/008545 WO1994000136A1 (en) 1992-06-30 1992-10-21 A COMBINATION OF ANTI-erbB-2 MONOCLONAL ANTIBODIES AND METHOD OF USING

Publications (2)

Publication Number Publication Date
EP0655924A1 EP0655924A1 (en) 1995-06-07
EP0655924A4 true EP0655924A4 (en) 1996-09-11

Family

ID=25422648

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93906955A Withdrawn EP0655924A4 (en) 1992-06-30 1992-10-21 A COMBINATION OF MONOCLONAL ANTIBODIES AGAINST erbB-2 AND METHOD FOR THEIR USE.

Country Status (6)

Country Link
EP (1) EP0655924A4 (ja)
JP (1) JPH08504172A (ja)
KR (1) KR100269879B1 (ja)
AU (1) AU687346B2 (ja)
CA (1) CA2120745A1 (ja)
WO (1) WO1994000136A1 (ja)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6733752B1 (en) 1994-03-30 2004-05-11 The Trustees Of The University Of Pennsylvania Prevention of tumors with monoclonal antibodies against neu
US5759776A (en) * 1995-06-05 1998-06-02 California Pacific Medical Center Targets for breast cancer diagnosis and treatment
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
EP1947119A3 (en) 1997-12-12 2012-12-19 Genentech, Inc. Treatment of cancer with anti-erb2 antibodies in combination with a chemotherapeutic agent
EP1941905A1 (en) 1998-03-27 2008-07-09 Genentech, Inc. APO-2 Ligand-anti-her-2 antibody synergism
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
EP2283867B1 (en) 1999-06-25 2014-05-21 ImmunoGen, Inc. Methods of treatment using anti-ERBB antibody-maytansinoid conjugates
CN100340575C (zh) 1999-06-25 2007-10-03 杰南技术公司 人源化抗ErbB2抗体及其在制备药物中的应用
TR200200472T2 (tr) 1999-08-27 2002-06-21 Genentech, Inc. Anti-Erb B2 antikorları ile tedavi için dozajlar
CA2385528C (en) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US20030152572A1 (en) * 2000-04-06 2003-08-14 Yoshimi Homma Diagnostic and therapeutic agents for rheumatoid arthritis
SI2857516T1 (sl) 2000-04-11 2017-09-29 Genentech, Inc. Multivalentna protitelesa in njihove uporabe
CN102698265A (zh) 2000-05-19 2012-10-03 杰南技术公司 用于提高对ErbB 拮抗剂癌症治疗的有效应答可能性的基因检测试验
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
SI1501856T1 (sl) 2002-04-10 2013-04-30 Genentech, Inc. Variante protitelesa proti HER2
US20050276812A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
PT2263691E (pt) 2002-07-15 2012-11-12 Hoffmann La Roche Tratamento de cancro com o anticorpo anti-erbb2 monoclonal humanizado recombinante 2c4 (rhumab 2c4)
CN100408097C (zh) * 2002-10-10 2008-08-06 默克专利有限公司 双特异性抗erb-b抗体及其在肿瘤治疗中的用途
SI1549344T1 (sl) * 2002-10-10 2015-05-29 Merck Patent Gmbh FARMACEVTSKI SESTAVKI PROTI RECEPTORJEM ErbB1
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
SG195524A1 (en) 2003-11-06 2013-12-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
EP1737489B1 (en) 2004-04-08 2012-01-11 David B Agus ErbB2 antagonists for tumor pain therapy
KR20180091967A (ko) 2004-07-22 2018-08-16 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
KR20170134771A (ko) 2005-01-21 2017-12-06 제넨테크, 인크. Ｈｅｒ 항체의 고정 용량 투여법
KR101253576B1 (ko) 2005-02-23 2013-04-11 제넨테크, 인크. Ｈｅｒ 이량체화 억제제를 이용한 암 환자에서의 질환진행까지의 시간 또는 생존의 연장
SI2511301T1 (en) 2006-08-04 2018-05-31 MedImmune Limited, Human antibodies to ERBB 2
JP5726417B2 (ja) 2007-03-01 2015-06-03 シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ 組み換え抗上皮成長因子受容体抗体組成物
EP2899541A1 (en) 2007-03-02 2015-07-29 Genentech, Inc. Predicting response to a HER dimerisation inhbitor based on low HER3 expression
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
PL2171090T3 (pl) 2007-06-08 2013-09-30 Genentech Inc Markery ekspresji genów odporności guza na leczenie hamujące HER2
PL3327026T3 (pl) 2007-07-09 2020-02-28 Genentech, Inc. Zapobieganie redukcji wiązań disiarczkowych podczas rekombinacyjnego wytwarzania polipeptydów
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
CA2732856C (en) 2008-08-29 2018-08-28 Symphogen A/S Cancer treatment with a combination of two different anti-epidermal growth factor receptor antibodies
AR075896A1 (es) 2009-03-20 2011-05-04 Genentech Inc Anticuerpos anti-her (factor de crecimiento epidermico)
SG10201507044PA (en) 2009-05-29 2015-10-29 Hoffmann La Roche Modulators for her2 signaling in her2 expressing patients with gastric cancer
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
KR101822205B1 (ko) 2009-08-11 2018-01-25 제넨테크, 인크. 글루타민-비함유 세포 배양 배지에서의 단백질의 생성
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
AU2011239583A1 (en) 2010-04-15 2012-11-29 Alper Biotech, Llc Monoclonal antibodies against HER2 antigens, and uses therefor
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
EP2643353A1 (en) 2010-11-24 2013-10-02 Novartis AG Multispecific molecules
RU2586515C2 (ru) 2010-12-21 2016-06-10 Ф.Хоффманн-Ля Рош Аг Препарат антитела, обогащенного изоформами и способ его получения
EP2655413B1 (en) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
JP6297490B2 (ja) 2011-08-31 2018-03-20 ジェネンテック， インコーポレイテッド 診断マーカー
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
EP2788500A1 (en) 2011-12-09 2014-10-15 F.Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
KR20210090298A (ko) 2012-10-30 2021-07-19 에스퍼란스 파마슈티컬스, 인코포레이티드 항체/약물 컨쥬게이트 및 이의 사용 방법
KR102291355B1 (ko) 2012-11-30 2021-08-19 에프. 호프만-라 로슈 아게 Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법
KR101453462B1 (ko) 2013-05-16 2014-10-23 앱클론(주) Her2에 특이적으로 결합하는 항체
CA2943299A1 (en) 2014-04-11 2015-10-15 Medimmune, Llc Bispecific her2 antibodies
EP3131584B1 (en) 2014-04-16 2022-01-12 Biocon Limited Stable protein formulations comprising a molar excess of sorbitol
IL292708B1 (en) 2015-05-30 2024-04-01 Molecular Templates Inc Vaccine-free Shiga toxin A subunit scaffolds and cell-targeting molecules containing them
AU2016280159A1 (en) 2015-06-17 2017-12-07 Genentech, Inc. Anti-HER2 antibodies and methods of use
JP7386796B2 (ja) 2017-11-14 2023-11-27 グリーン クロス ラボ セル コーポレーション 抗－ｈｅｒ２抗体又はその抗原結合フラグメント、及びこれを含むキメラ抗原受容体
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
CA3097178A1 (en) 2018-04-17 2019-10-24 Molecular Templates, Inc. Her2-targeting molecules comprising de-immunized, shiga toxin a subunit scaffolds
EP3560945A1 (en) 2018-04-27 2019-10-30 F. Hoffmann-La Roche AG Methods for purification of polypeptides using polysorbates
JP2022532812A (ja) * 2018-08-16 2022-07-20 カンタージア アクチエボラーグ 抗ｉｌ１ｒａｐ抗体組成物
WO2023044483A2 (en) 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0331034A2 (en) * 1988-02-26 1989-09-06 Neorx Corporation Functionally specific antibodies
WO1991005264A1 (en) * 1989-09-29 1991-04-18 Oncogenetics Partners Detection and quantification of neu related proteins in the biological fluids of humans

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0331034A2 (en) * 1988-02-26 1989-09-06 Neorx Corporation Functionally specific antibodies
WO1991005264A1 (en) * 1989-09-29 1991-04-18 Oncogenetics Partners Detection and quantification of neu related proteins in the biological fluids of humans

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KASPRZYK ET AL: "THERAPY OF AN ANIMAL MODEL OF HUMAN GASTRIC CANCER USING A COMBINATION OF ANTI-ERBB-2 MONOCLONAL ANTIBODIES", CANCER RESEARCH, vol. 52, 15 May 1992 (1992-05-15), pages 2771 - 2776, XP002014292 *
See also references of WO9400136A1 *

Also Published As

Publication number Publication date
CA2120745A1 (en) 1994-01-06
KR950700075A (ko) 1995-01-16
AU687346B2 (en) 1998-02-26
WO1994000136A1 (en) 1994-01-06
KR100269879B1 (ko) 2000-10-16
EP0655924A1 (en) 1995-06-07
AU3773393A (en) 1994-01-24
JPH08504172A (ja) 1996-05-07

Similar Documents

Publication Publication Date Title
EP0655924A4 (en) A COMBINATION OF MONOCLONAL ANTIBODIES AGAINST erbB-2 AND METHOD FOR THEIR USE.
ZA949341B (en) Humanized antibodies and uses thereof
PL311926A1 (en) Anti-alphav-integrinic monoclonal antibodies
AU4289496A (en) Method of promoting an immune response with a bispecific antibody
AU4618193A (en) Humanized antibodies
EP0676966A4 (en) Antibodies directed against binding associated epitopes.
NZ230786A (en) A method of reducing the heterogeneity of secreted monoclonal antibodies
EP0578515A3 (en) Humanized monoclonal antibodies.
GB9608626D0 (en) Hepatitis b monoclonal antibodies
IL90017A0 (en) Monoclonal antibodies
ZA898777B (en) Monoclonal antibodies
EP0506523A3 (en) Monoclonal antibodies
EP0909278A4 (en) IMMUNOGLOBULIN G LINKED TO NEPHROPATHY AND ANTIBODIES AGAINST IT
EP0218587A4 (en) MONOCLONAL ANTIBODIES AND IMMUNIZATION METHOD USING THE SAME.
EP0586026A3 (en) Characterization of a new anti-p110RB monoclonal antibody.
ZA89258B (en) Monoclonal antibodies
AU9143991A (en) Monoclonal antibody op-g2 and method of use
GB8820036D0 (en) Monoclonal antibodies
EP0582450A3 (en) Antibodies against oxytocin receptor and their production.
EP0654532A4 (en) ANTIMUCOGLYCOPROTEIN MONOCLONAL ANTIBODIES.
EP0468056A4 (en) Anti-procollagenase monoclonal antibodies and a method for the assay of procollagenase utilizing thereof
ZA912136B (en) Anti-oncostatin m monoclonal antibodies
EP0520436A3 (en) Monoclonal antibody, method of production thereof and use thereof
GB9220228D0 (en) Reshaped monoclonal antibodies against an immunologlobulin isotype
GB9212074D0 (en) Monoclonal antibody

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940505

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE

RHK1 Main classification (correction)

Ipc: A61K 35/14

RHK1 Main classification (correction)

Ipc: C12N 15/13

A4 Supplementary search report drawn up and despatched

Effective date: 19960726

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE

17Q First examination report despatched

Effective date: 20000712

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010123